智能科学与技术学报2024，Vol.6Issue(1)：88-99,12.DOI:10.11959/j.issn.2096-6652.202409
平行药物系统:基于大语言模型和三类人的框架与方法
Parallel drug systems:framework and methods based on large language models and three types of humans
摘要
Abstract
With the rapid development of the next generation of artificial intelligence technologies,such as the internet of things,large language models,and multimodal interactions,the traditional processes of drug research and production pro-cessing had been facing the challenges of an intelligent transition in recent years.In this context,this paper used the theory of parallel intelligence as the research philosophy and proposed a virtual-real interactive parallel drug systems,uti-lizing the ACP approach and large language models.It incorporated the concept of three types of beings—digital humans,robots,and natural persons—into the systems,providing a detailed discussion on the theoretical underpinnings,construc-tion techniques,and potential application scenarios of the systems.The parallel drug systems covered the entire process of the pharmaceutical industry.For the drug development phase,it considered processes such as drug discovery,laboratory research,and clinical trials.In the production processing phase,it encompassed pharmaceutical manufacturing operations and system analysis predictions.The medical healthcare subsystem included personalized medication consultation,aug-mented reality drug guidance,and privacy security.The whole systems open up a digitized"drug space",aiming to estab-lish a new paradigm for the drug systems and propel the revolution of intelligent medication.关键词
平行智能/ACP方法/大语言模型/三类人/平行药物系统/药物研发/药物生产加工/药物医疗保健Key words
parallel intelligence/ACP approach/large language models/three types of humans/parallel drug systems/drug research and development/drug production processing/medical healthcare分类
信息技术与安全科学引用本文复制引用
林飞,王飞跃,田永林,丁显廷,倪清桦,王静,申乐..平行药物系统:基于大语言模型和三类人的框架与方法[J].智能科学与技术学报,2024,6(1):88-99,12.基金项目
国家自然科学基金项目重点项目(No.61533019) （No.61533019）
澳门特别行政区科学技术发展基金(No.0093/2023/RIA2)The National Natural Science Foundation of China(No.61533019),The Science and Technology Development Fund,Macao SAR(No.0093/2023/RIA2) （No.0093/2023/RIA2）
